Thank you, Madam Chair and all the members of the committee, for inviting me.
I'm here today on behalf of the Canadian Hemophilia Society. It's an organization that represents people with bleeding orders that has chapters in each province of the country. In many ways, though, I am here to speak from my personal perspective on behalf of the organization. The organization hasn't taken a particular position on this issue yet, but I think my issues are reflective of some of the thinking right now.
Why this issue most matters to me is that I am likely going to need a liver transplant before I die. If I can get one, it may prevent my death. I'm infected with HIV and hepatitis C. I have cirrhosis of the liver. It's not decompensated, so I'm able to manage day to day, and I don't look particularly unhealthy. But I'm certainly aware that my likelihood of requiring a transplant is quite high, so it is incredibly important to me that we make available as many organs as possible.
Of course, I'm also well aware of the importance of the precautionary principle in public health care. The Canadian Hemophilia Society has been devastated over the years by the tainted blood tragedy and has done a lot of thinking about how we, as a society, go about balancing the need for precaution, in terms of infection, versus the need for transplant of these life-giving organs or for transfusion of blood.
Given the history of tainted blood and my own experiences in responding to that, I am also well aware of the importance of informed consent for patients when they are receiving health care--complete, fully informed consent.
There have been some comments today about the science in this matter. You have a lot of information on record on that. I think it really boils down to the precautionary principle and understanding how we deal with the science of probability versus the science of the specific incidence of infectious transmission. That's a debate that has to continue, and it has to be continued in public. It has to be understood by the public. It's an important debate, because at its heart, it is where we get into this issue of discrimination in these situations.
In particular, I want to respond to the suggestion that new testing methods are the answer to our problems. What we've learned through the blood transfusion situation, and are also recognizing in organ transplant, is the importance of both screening and testing together. It's never going to be perfectly safe. Things will always go wrong. Things will slip through the best systems. What we do is put in as many systems as possible to ensure that we minimize the damage done because of the need for transplants and the need for blood. The perfect world would be the world in which we didn't have transplants and we didn't have transfusions because we didn't have accidents and we didn't have disease and we didn't have problems that required them.
I don't want to spend a lot of time today, because I think you also have information on record. Certainly a lot of this is in the background to the development of the regulations, but there are specific, significant differences between blood donation and the system for blood donation and the transplant situation. In particular, there is the volume of blood donation. We don't have a serious shortage, despite there being shortages at different times of the year. With blood transfusion, we don't have the same type of shortage, so obviously larger blanket precautionary approaches are reasonable in that case.
In the organ donor situation--although these regulations obviously involve a lot more than what are really few solid organ donations in this country--the lack of availability of those particular organs means that people, on an individual basis, may be prepared to make different choices. We believe that what is important is the choice of the individual.
The fact that there is the exceptional distribution clause in the regulations gives us some confidence that at the end of the day, the individual patient and the doctor will ultimately decide, based on the best information available to them.
I also want to talk about why I think this particular situation has become so controversial, and then I will end with why I feel, from my reading of what the discussion has been, that we've actually missed what the real controversy is here.
Why is this controversial?
As a lawyer, as I looked over the record of how these regulations were developed, I was actually quite impressed with the process. One difficulty that I saw when the media report came out was that people started to wonder where this all came from. I went to meetings subsequently and people were standing up saying, “I couldn't find these regulations. Where were they? It took me days to track all this information down.”
Frankly, I had found it all in about 20 minutes, and I immediately realized that was because I'd been trained as a lawyer. I went immediately to the regulatory scheme and tracked it that way. Other people looked to the Health Canada website and to where they were used to finding the information. Clearly there was a communications problem at the end of this process and perhaps during the process.
I believe CBC did a lot of the original stories that came out, but it's quite apparent that not much background research had been done. That's tremendously unfortunate, because I think some messages were immediately sent out across the country that simply were not reflective of what the case is here.
As well, clearly this is going to be a living document. These regulations over time are going to change and grow. Science will tell us different and new things. Society will change. Culture will change. There will be changes over time.
Was the reaction to these regulations warranted?
I took a look at the exclusion criteria. As a person with hemophilia who has received a blood product in my life--and it doesn't matter when, or how many years ago, or my present situation--I would be banned from giving an organ donation. I have HIV and I have hepatitis C. I'm on the exclusion list. Also, people who have been bitten by a rabid animal are excluded, but there's already been a controversy, and probably that's not as broad as it should be. If anyone has been exposed to one--and thanks to some years on a sheep farm, I've been exposed to rabid animals over the years, so I'm excluded for that reason.
Am I concerned about this policy? Am I here to fight for it and champion it because I'm worried about infections getting through in that organ that I may get someday down the road? In some ways I'm not as concerned about that. I don't think my reaction to this whole controversy is related to that as much as to the fact that clearly I'm in the most excluded group there is.
Obviously why the MSM population is so concerned about this is the history of discrimination against that population in the country. As I reflected on that, I also asked myself what the closest I'd ever come to feeling that feeling I hear expressed at so many meetings I go to and hear from gay men and lesbian women. The closest I've been to feeling it was probably in high school where as a hemophiliac I was often prevented from taking part in the sort of macho tough-guy sports. I'd often get concerned that people would think I was gay. Thinking about that makes me think a lot about our society and makes me understand the reaction to policies like this. I think we all have a part to play and a part in the blame for that history.
I don't want to be trite, but I think in any other circumstances this would not be an issue. Again, when you look at it from a probability perspective, from a precautionary principle perspective, at the rates of infection in the population, and our ability to narrow on the basis of what are usable criteria, the MSM population is high on that list, as are people who have received blood products in the past, people who used injection drugs that were not prescribed, and people who have tattoos from using shared equipment.
I won't go into it now. I think there is some tinkering to be done on the details of the regulations. But clearly, as I am involved in AIDS and hepatitis C work, consistently we look at the MSM population as a whole, a specific target population for messaging and campaigns to reduce the infection rate in that community along with a lot of those other communities. So that is going to be there for a while.
That's speaks to something, though, another failure for us, and that is our inability to really do a good job working with those communities to reduce the infection levels. We have to ensure that resources are available to do that for them.
The real controversy I wanted to speak to today was the meeting I—